Technical Analysis for ICPT - Intercept Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
A 20.75 -4.42% -0.96
ICPT closed down 4.42 percent on Wednesday, February 8, 2023, on approximately normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Feb 28
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
New 52 Week High Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
New 52 Week Closing High Bullish -4.42%
Pocket Pivot Bullish Swing Setup -4.42%
New 52 Week High Strength -4.42%
Upper Bollinger Band Walk Strength -4.42%
Wide Bands Range Expansion -4.42%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 11 hours ago
Down 2 % about 13 hours ago
60 Minute Opening Range Breakdown about 13 hours ago
Rose Above Previous Day's High about 14 hours ago
New 52 Week High about 14 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Intercept Pharmaceuticals, Inc. Description

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea. The company is also developing INT-767, an orally administered FXR and TGR5 agonist, which is in preclinical studies to treat fibrosis; and INT-777, an orally administered TGR5 agonist that has completed preclinical studies for the treatment of type 2 diabetes. It has strategic collaborations and research agreements with Dainippon Sumitomo Pharma Co. Ltd. and TES Pharma Srl. The company was founded in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals, Inc. is a subsidiary of Genextra S.p.A.


Sector: Healthcare
Industry: Biotechnology
Keywords: Acid Alcohol Diabetes Hypertension Gastroenterology Steatohepatitis Diarrhea Liver Disease Hepatology Fibrosis Digestive Diseases Bile Acid Chronic Liver Disease Chronic Liver Diseases Primary Biliary Cholangitis Cirrhosis Farnesoid X Receptor Fxr Obeticholic Acid

Is ICPT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 21.86
52 Week Low 10.81
Average Volume 788,553
200-Day Moving Average 15.49
50-Day Moving Average 15.36
20-Day Moving Average 17.74
10-Day Moving Average 19.30
Average True Range 1.01
RSI 70.41
ADX 42.32
+DI 39.93
-DI 7.52
Chandelier Exit (Long, 3 ATRs) 18.83
Chandelier Exit (Short, 3 ATRs) 17.09
Upper Bollinger Bands 21.52
Lower Bollinger Band 13.96
Percent B (%b) 0.9
BandWidth 42.62
MACD Line 1.60
MACD Signal Line 1.27
MACD Histogram 0.3304
Fundamentals Value
Market Cap 684.59 Million
Num Shares 33 Million
EPS -10.44
Price-to-Earnings (P/E) Ratio -1.99
Price-to-Sales 3.90
Price-to-Book 44.19
PEG Ratio -0.69
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 22.42
Resistance 3 (R3) 22.60 22.23 22.14
Resistance 2 (R2) 22.23 21.81 22.14 22.04
Resistance 1 (R1) 21.49 21.54 21.31 21.31 21.95
Pivot Point 21.12 21.12 21.03 21.03 21.12
Support 1 (S1) 20.38 20.70 20.20 20.20 19.55
Support 2 (S2) 20.01 20.43 19.92 19.46
Support 3 (S3) 19.27 20.01 19.36
Support 4 (S4) 19.09